Double-blind, Randomized Controlled Study in Non-Hodgkin's Lymphoma

Study Title
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
Teva Identifier
NHL-TL011-102
ClinicalTrials.gov Identifier
NCT01205737
Study Status
Completed
Trial Condition(s)
DLBCL
Interventions
Biological: TL011 | Biological: Rituximab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 80 Years
Trial Duration
09/01/2010 - 09/01/2013
Phase
Phase 1

Study Type

Interventional